Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRevolution Beauty Regulatory News (REVB)

Share Price Information for Revolution Beauty (REVB)

Share Price is delayed by 15 minutes
Get Live Data
4.92    0.07 (1.44%)
Bid:
4.90
Ask:
5.02
Spread: 0.12 (2.449%)
Market Cap: £42.79m
REVB Live PriceLast checked at - London Stock Exchange

Intraday Revolution Beauty Share Chart

New Licensing Partnership with Debenhams Group

8 Jun 2026 07:00

RNS Number : 3654H
Revolution Beauty Group PLC
08 June 2026
 

8 June 2026

 

REVOLUTION BEAUTY GROUP PLC

("Revolution Beauty", the "Group" or the "Company")

 

NEW LICENSING PARTNERSHIP WITH DEBENHAMS GROUP

 

Revolution Beauty (AIM:REVB), the multi-channel mass beauty brand, is pleased to announce that the Boards of Debenhams Group and Revolution Beauty have agreed a new licensing partnership to develop beauty and fragrance products across Debenhams Group brands.

 

The partnership combines Revolution Beauty's expertise in developing, manufacturing and distributing beauty products with the strength and reach of Debenhams Group's full brand portfolio of fashion and lifestyle brands.

 

The first collections are expected to launch ahead of Christmas and will include fragrance and gifting ranges for PrettyLittleThing, Karen Millen and boohooMAN. Further beauty and fragrance launches are planned across a number of Debenhams Group brands, with products expected to be available through both Debenhams Group channels and selected retail partners.

 

Tom Allsworth, CEO of Revolution Beauty, said: "We are delighted to formally announce our partnership with Debenhams Group. The team at Revolution is already at an advanced stage in developing fragrance products that will launch nationally and internationally through a number of our retail partners. The early reaction to the concepts we have tested has been exceptionally positive.

 

"Since returning to the business last year, our relationship with Debenhams Group has been completely reset and it is gratifying to see that reflected in a formal partnership between the two businesses. By combining the strength of Debenhams Group's brands with Revolution's expertise, we believe these licences can become a significant growth opportunity for both businesses."

 

Dan Finley, CEO of Debenhams Group, said: "We have been clear that we see significant global licensing opportunities for our brands, and this agreement with Revolution Beauty is a direct expression of our asset-lite strategy in action. Beauty is one of the most compelling category opportunities available to us and Revolution Beauty has the capability and relationships to bring tailored collections to market across the full portfolio. We look forward to seeing the first launches come to life.

 

"The agreement is structured as a royalty-based license, where Revolution Beauty assumes full responsibility for product development, manufacturing, and worldwide distribution and will pay to Debenhams Group an industry-standard royalty based on sales of the products developed. Debenhams Group retains brand approval rights over all products, packaging, marketing, and retail channel decisions.

 

"This transaction is consistent with Debenhams Group's strategy of generating significant recurring royalty income from its IP portfolio through global licensing opportunities, extending its brands into high-growth adjacent categories, and accelerating its transition to an asset-lite business model."

 

Related party transaction for Revolution Beauty

The licensing agreement with Debenhams Group constitutes a related party transaction for Revolution Beauty under Rule 13 of the AIM Rules for Companies by virtue of Debenhams Group being a substantial shareholder of Revolution Beauty. The directors of Revolution Beauty, who are all independent of Debenhams Group, consider, having consulted with the Company's nominated adviser, Strand Hanson Limited, that the terms of this related party transaction are fair and reasonable insofar as the shareholders of Revolution Beauty are concerned.

 

This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended.

 

For further information please contact

 

Investor relations Tom Allsworth, CEO

Neil Catto, CFO

Investor.relations@revolutionbeautyplc.com

Strand Hanson Limited (Nominated Adviser)

Christopher Raggett/Carl Holmes/Imogen Ellis

Tel: +44 (0)20 7409 3494

Zeus Capital (Broker)

Dominic King/Jordan WarburtonTel: +44 (0)161 831 1512

 

Tavistock (media enquiries)

Simon Hudson/Rebecca Hislaire/Saskia Sizen+44 (0)20 7920 3150

 

About Revolution Beauty

Revolution Beauty is a global mass beauty and personal care business which operates a multi brand, multi category strategy and sells its products both direct-to-consumer (DTC) via its e-commerce operations, and in physical and digital retailers through wholesale relationships.

 

Today, the Group has a retail footprint of c.17,500 doors across leading retail chains in the UK, USA and other international markets. Revolution Beauty has access to a wide customer base, predominantly aged between 16 and 35, through its digital partners and own DTC platform. It has established and invested to streamline its supply chain with its own manufacturing facility in the UK, and third-party warehousing facilities across the UK and in the USA. The Group has offices in the UK and the USA. Revolution Beauty currently employs 231 people.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDLBSGDGLR
Date   Source Headline
8th Jun 20267:00 amRNSNew Licensing Partnership with Debenhams Group
5th Jun 20267:00 amRNSFinancial Conduct Authority Update
16th Apr 20267:00 amRNSGrant of Share Options
1st Apr 202611:35 amRNSTotal Voting Rights
11th Mar 20267:00 amRNSAppointment of Nominated Adviser
2nd Mar 202611:28 amRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jan 20263:48 pmRNSTotal Voting Rights
15th Dec 20256:18 pmRNSDirector/PDMR Shareholding
1st Dec 20255:43 pmRNSTotal Voting Rights
27th Nov 20253:59 pmRNSDirector/PDMR Shareholding
27th Nov 20257:00 amRNSInterim Results
26th Nov 20256:15 pmRNSRelated Party Transaction
4th Nov 20254:32 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20259:33 amRNSResult of AGM
24th Sep 20257:00 amRNSDirectorate Change
18th Sep 20257:00 amRNSHolding(s) in Company
17th Sep 202512:30 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSDirector/PDMR Shareholding
16th Sep 20255:17 pmRNSHolding(s) in Company
16th Sep 20259:11 amRNSHolding(s) in Company
11th Sep 20254:09 pmRNSResults of General Meeting
2nd Sep 20258:30 amRNSTotal Voting Rights
1st Sep 20255:06 pmRNSHolding(s) in Company
1st Sep 20258:33 amRNSHolding(s) in Company
29th Aug 20254:50 pmRNSFinal Results, Annual Report Posting & AGM Notice
26th Aug 20257:01 amRNSCircular Publication, Notice of GM & Board Update
26th Aug 20257:00 amRNSResult of Retail Offer to existing shareholders
22nd Aug 20254:31 pmRNSPDMR Dealing
22nd Aug 20253:30 pmRNSHolding(s) in Company
22nd Aug 20258:52 amRNSHolding(s) in Company
22nd Aug 20258:40 amRNSRetail Offer to existing shareholders
22nd Aug 20258:09 amRNSResult of Placing and Subscription
22nd Aug 20257:02 amRNSProposed Placing and Subscription via ABB
22nd Aug 20257:01 amRNSPreliminary Unaudited Results
22nd Aug 20257:00 amRNSTermination of Formal Sale Process
21st Aug 202510:51 amRNSForm 8.5 (EPT/RI)
20th Aug 202510:28 amRNSForm 8.5 (EPT/RI)
19th Aug 202512:27 pmRNSFY25 Trading Update
19th Aug 202510:01 amRNSForm 8.5 (EPT/RI)
18th Aug 202510:27 amRNSForm 8.5 (EPT/RI)
15th Aug 20254:11 pmRNSHolding(s) in Company
15th Aug 20259:57 amRNSForm 8.5 (EPT/RI)
14th Aug 202510:25 amRNSForm 8.5 (EPT/RI)
13th Aug 202510:31 amRNSForm 8.5 (EPT/RI)
12th Aug 202510:05 amRNSForm 8.5 (EPT/RI)
11th Aug 202510:26 amRNSForm 8.5 (EPT/RI)
8th Aug 202511:31 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.